Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Construction and Validation of a Clinical Cohort on the Pathogenesis Evolution and Syndrome-Differentiated Treatment of Chronic Obstructive Pulmonary Disease Based on Core Targets of Airway Inflammation and Remodeling

11 listopada 2026 zaktualizowane przez: First Affiliated Hospital of Ningbo University

This multicenter, randomized, open-label clinical trial will enroll 360 adults with chronic obstructive pulmonary disease (COPD): 240 with stable COPD and 120 hospitalized with an acute exacerbation (AECOPD). Participants will be stratified by disease stage and traditional Chinese medicine (TCM) syndrome. Within each syndrome stratum, they will be assigned to standardized Western medical treatment alone or the same treatment plus a syndrome-specific optimized herbal formula; selected strata will also include an innovative herbal formula group. Stable-phase participants will receive the study herbal treatment for 12 weeks, and AECOPD participants for 2 weeks. Both cohorts will be followed for 24 weeks. The study will assess lung function and exacerbations in stable COPD, and early dyspnea improvement and length of hospital stay in AECOPD. It will also assess symptoms, quality of life, TCM syndrome scores, safety, and biological markers.

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

360

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Guangdong
      • Dongguan, Guangdong, Chiny
        • Dongguan People's Hospital
        • Kontakt:
      • Guangzhou, Guangdong, Chiny
        • The First Affiliated Hospital of Guangzhou Medical University
        • Kontakt:
    • Henan
      • Zhengzhou, Henan, Chiny
        • The First Affiliated Hospital of Henan University of Chinese Medicine
        • Kontakt:
    • Zhejiang
      • Ningbo, Zhejiang, Chiny, 315000
        • The First Affiliated Hospital of Ningbo University
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

40 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria - Stable COPD cohort:

  1. COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70.
  2. Age 40 years or older, any sex.
  3. Clinically stable during the 4 weeks before enrollment, without a COPD exacerbation or initiation/change of systemic antibiotics or systemic glucocorticoids for worsening respiratory symptoms.
  4. Predominant TCM syndrome of lung qi deficiency, lung-spleen qi deficiency, lung-kidney qi deficiency, or lung-kidney qi-yin deficiency, according to the 2011 TCM syndrome diagnostic criteria for COPD.
  5. Able to understand the study and provide written informed consent.
  6. Able to complete clinical assessments, sample collection, and follow-up.

Exclusion Criteria - Stable COPD cohort:

  1. Systemic antibiotics or systemic glucocorticoids within 2 weeks before enrollment, or long-term systemic glucocorticoid maintenance therapy.
  2. TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
  3. Active pulmonary tuberculosis, pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
  4. Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
  5. Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
  6. Allergy to study herbal components or a contraindication to herbal therapy.
  7. Pregnancy, breastfeeding, or planned pregnancy.
  8. Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
  9. Investigator judges participation unsuitable.

Inclusion Criteria - Hospitalized AECOPD cohort:

  1. COPD diagnosed on clinical grounds and post-bronchodilator FEV1/FVC <0.70; current acute exacerbation assessed clinically.
  2. Age 40 years or older, any sex.
  3. Hospitalized for the current AECOPD episode, with screening and randomization completed within 24 hours after admission.
  4. Onset of acute worsening of respiratory symptoms no more than 5 days before enrollment.
  5. Cumulative systemic antibiotic and/or systemic glucocorticoid treatment for the current episode no more than 48 hours before enrollment.
  6. Predominant TCM syndrome of phlegm-heat obstructing the lung or phlegm-turbidity obstructing the lung, according to the 2011 TCM syndrome diagnostic criteria for COPD.
  7. Able to understand the study and provide written informed consent.
  8. Able to complete clinical assessments, sample collection, and follow-up.

Exclusion Criteria - Hospitalized AECOPD cohort:

  1. Deterioration not attributable to AECOPD; active pulmonary tuberculosis, invasive fungal disease, or pulmonary infection requiring pathogen-specific treatment as judged by the investigator.
  2. Pulmonary embolism, lung tumor, or another clearly diagnosed respiratory disease.
  3. Systemic antibiotics or systemic glucocorticoids for reasons other than the current exacerbation within 2 weeks, or long-term systemic glucocorticoid maintenance therapy.
  4. TCM decoctions, patent medicines, or granules for COPD, cough, wheeze, or sputum within 2 weeks when judged likely to affect efficacy assessment.
  5. Immediate need for intensive care, invasive mechanical ventilation, altered consciousness, or hemodynamic instability at enrollment.
  6. Prior major pulmonary surgery, including lung volume reduction surgery or lung transplantation.
  7. Severe cardiac, hepatic, renal, or hematologic disease, or psychiatric disease preventing cooperation.
  8. Allergy to study herbal components or a contraindication to herbal therapy.
  9. Pregnancy, breastfeeding, or planned pregnancy.
  10. Blood transfusion within 4 weeks, participation in another interventional clinical study, or history of alcohol or drug abuse.
  11. Investigator judges participation unsuitable.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Stable COPD - Lung Qi Deficiency - Optimized Yuping Yifei Formula

24 participants with stable COPD and lung qi deficiency receive the optimized Yuping Yifei herbal formula plus standardized Western medical treatment for 12 weeks.

Stable COPD, lung qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fangfeng 6 g, Wuweizi 6 g, Ziwan 9 g, and Sangbaipi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Aktywny komparator: Stable COPD - Lung Qi Deficiency - Standard Western Treatment

24 participants with stable COPD and lung qi deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Eksperymentalny: Stable COPD - Lung-Spleen Qi Deficiency - Optimized Liujun Fuzheng Formula

24 participants with stable COPD and lung-spleen qi deficiency receive the optimized Liujun Fuzheng herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 12 g, Chenpi 9 g, ginger-processed Banxia 9 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Eksperymentalny: Stable COPD - Lung-Spleen Qi Deficiency - Innovative Qiyi Peitu Formula

24 participants with stable COPD and lung-spleen qi deficiency receive the innovative Qiyi Peitu herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-spleen qi deficiency: Huangqi 30 g, Dangshen 15 g, stir-fried Baizhu 12 g, Fuling 15 g, Shanyao 20 g, Yiyiren 20 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Aktywny komparator: Stable COPD - Lung-Spleen Qi Deficiency - Standard Western Treatment

24 participants with stable COPD and lung-spleen qi deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Eksperymentalny: Stable COPD - Lung-Kidney Qi Deficiency - Optimized Shenqi Naqi Formula

24 participants with stable COPD and lung-kidney qi deficiency receive the optimized Shenqi Naqi herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-kidney qi deficiency: Dangshen 20 g, Huangqi 30 g, salt-processed Duzhong 12 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Fuling 12 g, and ginger-processed Banxia 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Eksperymentalny: Stable COPD - Lung-Kidney Qi Deficiency - Innovative Fufei Gushen Formula

24 participants with stable COPD and lung-kidney qi deficiency receive the innovative Fufei Gushen herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-kidney qi deficiency: Huangqi 30 g, Renshen 6 g, Yinyanghuo 9 g, Buguzhi 9 g, Shanzhuyu 12 g, Wuweizi 6 g, Gouqizi 15 g, and honey-processed Gancao 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Aktywny komparator: Stable COPD - Lung-Kidney Qi Deficiency - Standard Western Treatment

24 participants with stable COPD and lung-kidney qi deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Eksperymentalny: Stable COPD - Lung-Kidney Qi-Yin Deficiency - Optimized Shengmai Runyuan Formula

24 participants with stable COPD and lung-kidney qi-yin deficiency receive the optimized Shengmai Runyuan herbal formula plus standardized Western medical treatment for 12 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Stable COPD, lung-kidney qi-yin deficiency: Dangshen 15 g, Zhemaidong 10 g, Wuweizi 6 g, Shudihuang 15 g, Shanzhuyu 12 g, Shanyao 20 g, Huangqi 30 g, and Danshen 15 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 12 weeks, added to routine health education and guideline-based Western treatment.

Aktywny komparator: Stable COPD - Lung-Kidney Qi-Yin Deficiency - Standard Western Treatment

24 participants with stable COPD and lung-kidney qi-yin deficiency receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Eksperymentalny: AECOPD - Phlegm-Heat Obstructing Lung - Optimized Qinbei Qingfei Formula

24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive the optimized Qinbei Qingfei herbal formula plus standardized Western medical treatment for 2 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Hospitalized AECOPD, phlegm-heat obstructing the lung: Huangqin 9 g, Zhebeimu 10 g, Sangbaipi 12 g, Yuxingcao 20 g, Qingbanxia 9 g, Zisuzi 9 g, and honey-processed Mahuang 5 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

Aktywny komparator: AECOPD - Phlegm-Heat Obstructing Lung - Standard Western Treatment

24 hospitalized participants with AECOPD and phlegm-heat obstructing the lung receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Eksperymentalny: AECOPD - Phlegm-Turbidity Obstructing Lung - Optimized Erchen Shunqi Formula

24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the optimized Erchen Shunqi herbal formula plus standardized Western medical treatment for 2 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Zisuzi 9 g, Baijiezi 6 g, and Laifuzi 9 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

Eksperymentalny: AECOPD - Phlegm-Turbidity Obstructing Lung - Innovative Banlou Kuanxiong Formula

24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive the innovative Banlou Kuanxiong herbal formula plus standardized Western medical treatment for 2 weeks.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Hospitalized AECOPD, phlegm-turbidity obstructing the lung: ginger-processed Banxia 9 g, Houpo 9 g, Chenpi 9 g, Fuling 12 g, Gualoupi 9 g, Gualouren 6 g, Kuxingren 9 g, and Jiegeng 6 g per daily dose. Decoction 400 mL/day in two 200 mL doses after meals for 2 weeks, added to standardized Western treatment.

Aktywny komparator: AECOPD - Phlegm-Turbidity Obstructing Lung - Standard Western Treatment

24 hospitalized participants with AECOPD and phlegm-turbidity obstructing the lung receive standardized Western medical treatment without the study herbal formula.

Administer standardized Western medical treatment in accordance with the GOLD guidelines

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in FEV1 Percent Predicted at Week 24 (Stable COPD)
Ramy czasowe: Baseline (T0) and Week 24

Absolute change from baseline in post-bronchodilator forced expiratory volume in one second as a percentage of the predicted value (FEV1%pred).

Baseline (T0) and Week 24
Time to First Hospitalized COPD Exacerbation Through Week 24 (Stable COPD)
Ramy czasowe: From baseline (T0) through Week 24

Time from T0 to the first acute COPD exacerbation requiring hospitalization. Exacerbations managed without hospitalization are not counted for this outcome.

From baseline (T0) through Week 24
Number of Hospitalized COPD Exacerbations Through Week 24 (Stable COPD)
Ramy czasowe: From baseline (T0) through Week 24

Count of acute COPD exacerbations requiring hospitalization from T0 through Week 24. Episodes treated only in outpatient or emergency settings without admission are not counted.

From baseline (T0) through Week 24
Change in Dyspnea Numeric Rating Scale Score on Day 4 (AECOPD)
Ramy czasowe: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)

Absolute change from baseline in the average dyspnea numeric rating scale (NRS) score over the preceding 24 hours.

Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
Proportion With at Least a 1-Point Improvement in Dyspnea NRS on Day 4 (AECOPD)
Ramy czasowe: Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)

Proportion of participants whose average dyspnea NRS score over the preceding 24 hours decreases by at least 1 point from baseline.

Baseline (T0) and Day 4 (72 ± 24 hours after treatment initiation)
Total Length of Hospital Stay for the Index AECOPD Admission
Ramy czasowe: From hospital admission to discharge for the index AECOPD episode

Number of days from admission for the index acute exacerbation to hospital discharge.

From hospital admission to discharge for the index AECOPD episode

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in COPD Assessment Test (CAT) Score
Ramy czasowe: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24

Change from baseline in CAT total score in the stable COPD and AECOPD cohorts.

Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
Change in TCM Syndrome Efficacy Score
Ramy czasowe: Baseline and scheduled assessments through Week 24

Change from baseline in the syndrome-specific TCM symptom score using the appropriate stable-phase or AECOPD assessment scale.

Baseline and scheduled assessments through Week 24
Change in St. George's Respiratory Questionnaire (SGRQ) Score
Ramy czasowe: Baseline, Week 12, and Week 24

Change from baseline in SGRQ total score.

Baseline, Week 12, and Week 24
Change in Modified Medical Research Council (mMRC) Dyspnea Grade
Ramy czasowe: Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24

Change from baseline in the mMRC dyspnea grade, an ordinal measure of breathlessness, in stable COPD and hospitalized AECOPD participants.

Stable COPD: baseline and Weeks 4, 8, 12, and 24; AECOPD: baseline, Days 4 and 7, and Weeks 2, 12, and 24
Change in Airway Wall Area Percentage on HRCT
Ramy czasowe: Baseline and Week 24

Absolute change from baseline in airway wall area percentage (WA%) derived from quantitative high-resolution computed tomography.

Baseline and Week 24
Change in Emphysema Index on HRCT
Ramy czasowe: Baseline and Week 24

Absolute change from baseline in emphysema index derived from quantitative high-resolution computed tomography.

Baseline and Week 24
Change in Airway Wall Thickness on HRCT
Ramy czasowe: Baseline and Week 24

Absolute change from baseline in airway wall thickness derived from quantitative high-resolution computed tomography.

Baseline and Week 24
Change in C-Reactive Protein Concentration
Ramy czasowe: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in peripheral-blood C-reactive protein concentration as an inflammation marker.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Interleukin-6 Concentration
Ramy czasowe: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in interleukin-6 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Interleukin-8 Concentration
Ramy czasowe: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in interleukin-8 concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in Tumor Necrosis Factor Alpha Concentration
Ramy czasowe: Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24

Absolute change from baseline in tumor necrosis factor alpha concentration measured in peripheral blood or induced sputum, where a safe sample is obtainable.

Stable COPD: baseline, Weeks 12 and 24; AECOPD: baseline, Weeks 2 and 24
Change in FEV1 Percent Predicted After AECOPD
Ramy czasowe: Baseline when feasible, Weeks 12 and 24

Absolute change from baseline in post-bronchodilator FEV1 percent predicted among hospitalized AECOPD participants able to undergo safe and valid spirometry.

Baseline when feasible, Weeks 12 and 24
Incidence of Adverse Events
Ramy czasowe: From baseline through Week 24

Number and proportion of participants experiencing at least one adverse event during treatment and follow-up, with event type, severity, and relationship to study herbal treatment recorded.

From baseline through Week 24
Incidence of Serious Adverse Events
Ramy czasowe: From baseline through Week 24

Number and proportion of participants experiencing at least one serious adverse event during treatment and follow-up, with severity, management, outcome, and relationship to study herbal treatment recorded.

From baseline through Week 24

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 kwietnia 2030

Ukończenie studiów (Szacowany)

1 maja 2030

Daty rejestracji na studia

Pierwszy przesłany

11 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 listopada 2026

Pierwszy wysłany (Rzeczywisty)

18 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

11 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data underlying the results reported in the main publication, including baseline characteristics, treatment allocation, and outcome data, will be available upon reasonable request. Direct personal identifiers will not be shared.

Ramy czasowe udostępniania IPD

Beginning after publication of the main study results, subject to applicable institutional and ethics requirements.

Kryteria dostępu do udostępniania IPD

Qualified researchers may request access by submitting a research proposal to the study contact, together with ethics approval where applicable. Requests will be reviewed by the study team and relevant institutional or ethics bodies. Approved researchers will receive de-identified data under a data-use agreement. Re-identification and onward sharing are prohibited.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj